| hsa04668 |
TNF signaling pathway |
11 |
1.30 × 10−17
|
AKT1, CASP3, CASP8, FOS, IL1B, JUN, MAPK8, MMP9, PTGS2, TNF, VCAM1 |
| hsa04657 |
IL-17 signaling pathway |
10 |
2.27 × 10−16
|
CASP3, CASP8, FOS, HSP90AA1, IL1B, JUN, MAPK8, MMP9, PTGS2, TNF |
| hsa05161 |
Hepatitis B |
10 |
1.08 × 10−14
|
AKT1, CASP3, CASP8, CASP9, FOS, JUN, MAPK8, MMP9, STAT1, TNF |
| hsa05152 |
Tuberculosis |
10 |
6.08 × 10−14
|
AKT1, CASP3, CASP8, CASP9, IL10, IL1B, MAPK8, NOS2, STAT1, TNF |
| hsa04010 |
MAPK signaling pathway |
9 |
2.33 × 10−10
|
AKT1, CASP3, FOS, IL1B, JUN, KDR, MAPK8, TNF, VEGFA |
| hsa05133 |
Pertussis |
8 |
3.76 × 10−13
|
CASP3, FOS, IL10, IL1B, JUN, MAPK8, NOS2, TNF |
| hsa04620 |
Toll-like receptor signaling pathway |
8 |
3.94 × 10−12
|
AKT1, CASP8, FOS, IL1B, JUN, MAPK8, STAT1, TNF |
| hsa04659 |
Th17 cell differentiation |
8 |
3.94 × 10−12
|
FOS, HSP90AA1, IL1B, IL2, JUN, MAPK8, SMAD2, STAT1 |
| hsa04210 |
Apoptosis |
8 |
2.75 × 10−11
|
AKT1, CASP3, CASP8, CASP9, FOS, JUN, MAPK8, TNF |
| hsa05168 |
Herpes simplex infection |
8 |
2.33 × 10−10
|
CASP3, CASP8, FOS, IL1B, JUN, MAPK8, STAT1, TNF |
| hsa05166 |
HTLV-I infection |
8 |
2.31 × 10−9
|
AKT1, FOS, IL2, JUN, MAPK8, SMAD2, TNF, VCAM1 |
| hsa04151 |
PI3K-Akt signaling pathway |
8 |
2.24 × 10−8
|
AKT1, CASP9, HSP90AA1, IL2, KDR, NOS3, PIK3CG, VEGFA |
| hsa05321 |
Inflammatory bowel disease (IBD) |
7 |
1.14 × 10−11
|
IL10, IL1B, IL2, JUN, SMAD2, STAT1, TNF |
| hsa04621 |
NOD-like receptor signaling pathway |
7 |
4.91 × 10−9
|
CASP8, HSP90AA1, IL1B, JUN, MAPK8, STAT1, TNF |
| hsa05164 |
Influenza A |
7 |
5.12 × 10−9
|
AKT1, CASP9, IL1B, JUN, MAPK8, STAT1, TNF |
| hsa05165 |
Human papillomavirus infection |
7 |
2.72 × 10−7
|
AKT1, CASP3, CASP8, PTGS2, STAT1, TNF, VEGFA |
| hsa04370 |
VEGF signaling pathway |
6 |
7.66 × 10−10
|
AKT1, CASP9, KDR, NOS3, PTGS2, VEGFA |
| hsa04660 |
T cell receptor signaling pathway |
6 |
1.09 × 10−8
|
AKT1, FOS, IL10, IL2, JUN, TNF |
| hsa04060 |
Cytokine–cytokine receptor interaction |
6 |
1.85 × 10−6
|
IL10, IL1B, IL2, KDR, TNF, VEGFA |
| hsa04658 |
Th1 and Th2 cell differentiation |
5 |
2.91 × 10−7
|
FOS, IL2, JUN, MAPK8, STAT1 |
| hsa05144 |
Jak-STAT signaling pathway |
4 |
1.28 × 10−6
|
AKT1, IL10, IL2, STAT1 |
| hsa04064 |
NF-kappa B signaling pathway |
4 |
1.41 × 10−5
|
IL1B, PTGS2, TNF, VCAM1 |
| hsa04066 |
HIF-1 signaling pathway |
4 |
1.66 × 10−5
|
AKT1, NOS2, NOS3, VEGFA |
| hsa04068 |
FoxO signaling pathway |
4 |
4.41 × 10−5
|
AKT1, IL10, MAPK8, SMAD2 |
| hsa05160 |
Hepatitis C |
4 |
4.41 × 10−5
|
AKT1, MAPK8, STAT1, TNF |
| hsa04630 |
Malaria |
4 |
8.87 × 10−5
|
IL10, IL1B, TNF, VCAM1 |
| hsa05169 |
Epstein–Barr virus infection |
4 |
0.00018 |
AKT1, IL10, JUN, MAPK8 |
| hsa04014 |
Ras signaling pathway |
4 |
0.00029 |
AKT1, KDR, MAPK8, VEGFA |
| hsa04662 |
B cell receptor signaling pathway |
3 |
0.00018 |
AKT1, FOS, JUN |
| hsa04920 |
Adipocytokine signaling pathway |
3 |
0.00018 |
AKT1, MAPK8, TNF |
| hsa01521 |
EGFR tyrosine kinase inhibitor resistance |
3 |
0.00024 |
AKT1, KDR, VEGFA |
| hsa04611 |
Platelet activation |
3 |
0.00078 |
AKT1, NOS3, PIK3CG |
| hsa05310 |
Asthma |
2 |
0.001 |
IL10, TNF |
| hsa04672 |
Intestinal immune network for IgA production |
2 |
0.0022 |
IL10, IL2 |
| hsa00590 |
Arachidonic acid metabolism |
2 |
0.0038 |
ALOX5, PTGS2 |
| hsa04750 |
Inflammatory mediator regulation of TRP channels |
2 |
0.0078 |
IL1B, MAPK8 |
| hsa05322 |
Systemic lupus erythematosus |
2 |
0.0081 |
IL10, TNF |
| hsa04670 |
Leukocyte transendothelial migration |
2 |
0.0111 |
MMP9, VCAM1 |
| hsa04062 |
Chemokine signaling pathway |
2 |
0.0236 |
AKT1, STAT1 |
